GlassScriptPhysician profile
Binu Valsan John
NPI 1790978187
$32,594.21
in general payments reported to CMS, 2019-2025
12 companies · $7,323 in 2025
The $7,323 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $3,000 · 2022: $15K · 2023: $5,500 · 2024: $26.70 · 2025: $7,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,320 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,213 · Travel and Lodging: $911 · Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,320.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,213.00 |
| Travel and Lodging | $911.30 |
| Food and Beverage | $405.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,303.81 | 2022 | |
| Exelixis INC. | $5,600.61 | 2019-2023 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $3,812.30 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $3,510.75 | 2025 | Rezdiffra |
| Dova Pharmaceuticals | $3,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $2,465.04 | 2022 | |
| Eisai INC. | $1,875.00 | 2019 | |
| Gilead Sciences, INC. | $26.70 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binu John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.